Loading

Our Team

Developing Innovative Drugs and Drug Combinations to Improve Clinical Outcomes in Advanced Cancer

Research Portfolio

Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive® (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Market Demand

The numbers behind our research define Validive and camsirubicin opportunities

Investment Opportunities

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Validive® (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of chemoradiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

Validive®

Radiation induced SOM in OPC

Completed Phase 2 Trial, Phase 3 ready Completed Phase 2 Trial, Phase 3 ready

Discovery complete

Completed Phase 2 Trial, Phase 3 ready Completed Phase 2 Trial, Phase 3 ready

Preclinical complete

Completed Phase 2 Trial, Phase 3 ready Completed Phase 2 Trial, Phase 3 ready

Phase 1 complete

Completed Phase 2 Trial, Phase 3 ready Completed Phase 2 Trial, Phase 3 ready

Phase 2 in progress

Completed Phase 2 Trial, Phase 3 ready Completed Phase 2 Trial, Phase 3 ready

Phase 3 not started

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

Camsirubicin (MNPR-201)

Advanced Soft Tissue Sarcoma

Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

Discovery complete

Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

Preclinical complete

Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

Phase 1 complete

Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

Phase 2 in progress

Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 Phase 2 Data in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

Phase 3 not started

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

MNPR-101

Advanced Solid Cancers

Pre-IND Pre-IND

Discovery complete

Pre-IND Pre-IND

Preclinical in progress

Pre-IND Pre-IND

Phase 1 not started

Pre-IND Pre-IND

Phase 2 not started

Pre-IND Pre-IND

Phase 3 not started